RELX PLC (RDEB) Fair Value & Analysis
Industrials · DE · Market cap €50.3B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 17 days ago
Share price −4.2% over the past month.
Price vs Fair Value (12 months)
12‑month range €22.97 – €45.10 · fair‑value band €11.80 – €22.39 · the €28.42 price screens above the €17.10 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
RELX PLC (RDEB) currently trades at €28.42, while our model-based Fair Value estimate is €17.10 — implying the stock looks roughly 39.8% overvalued today. We read business quality at 66/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, RELX PLC generated revenue of €9.6B at a net margin of 21.5%. Revenue grew 1.2% year over year. It earns a return on equity of 70.5%. Net debt stands at €7.2B. Fundamentals as of Jun 24, 2026
Our scenario range runs from €11.80 (bear case) to €22.39 (bull case); at €28.42, the current price sits above that range. The share trades about 39% below its 52-week high and 25% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -29% fair-value upside — at -40%, RDEB screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
RELX PLC, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Risk; Scientific, Technical & Medical; Legal; and Exhibitions. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk, as well as a portfolio of commercial healthcare products. Its Scientific, Technical & Medical segment provides scientific and medical information and data sets for science and healthcare. The Legal segment provides legal, regulatory, and business information and analytics. Its Exhibitions segment combines digital tools and data to help customers connect in-person and online, discover new markets, source products, generate leads, and transact. The company was formerly known as Reed Elsevier PLC and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
RELX PLC reported revenue of €9.6B in FY2025 versus €7.2B in FY2021, a compound +7.3%/yr. Reported net income was €2.1B in FY2025, compounding +8.9%/yr from FY2021.
Is RDEB fairly valued? → Check now
Similar stocks
10 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Cintas Corporation CTAS | $169.45 | $82.75 | -51% |
| Thomson Reuters Corporation TRI | C$120.12 | C$85.63 | -29% |
| Copart, Inc CPRT | $30.77 | $28.89 | -6% |
| Global Payments Inc GPN | $65.09 | $70.80 | +9% |
| UL Solutions Inc ULS | $89.71 | $30.99 | -65% |
| RB Global, Inc RBA | $104.49 | $46.94 | -55% |
| Brambles Limited BMBLF | $13.70 | $11.89 | -13% |
| Wolters Kluwer N.V WOSB | €56.62 | €103.04 | +82% |
| Rentokil Initial plc RTO | $28.50 | $19.63 | -31% |
| Aramark ARMK | $53.30 | $11.68 | -78% |
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is RELX PLC (RDEB) undervalued?
What is the fair value of RDEB?
What is the quality score of RDEB?
What is the revenue of RELX PLC (RDEB)?
What is the net profit margin of RDEB?
Does RELX PLC pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full RELX PLC analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.